Berhanu Aklile, Prigge Jonathan T, Silvera Peter M, Honeychurch Kady M, Hruby Dennis E, Grosenbach Douglas W
SIGA Technologies, Inc., Corvallis, Oregon, USA
Southern Research Institute, Frederick, Maryland, USA.
Antimicrob Agents Chemother. 2015 Jul;59(7):4296-300. doi: 10.1128/AAC.00208-15. Epub 2015 Apr 20.
The therapeutic efficacies of smallpox vaccine ACAM2000 and antiviral tecovirimat given alone or in combination starting on day 3 postinfection were compared in a cynomolgus macaque model of lethal monkeypox virus infection. Postexposure administration of ACAM2000 alone did not provide any protection against severe monkeypox disease or mortality. In contrast, postexposure treatment with tecovirimat alone or in combination with ACAM2000 provided full protection. Additionally, tecovirimat treatment delayed until day 4, 5, or 6 postinfection was 83% (days 4 and 5) or 50% (day 6) effective.
在致死性猴痘病毒感染的食蟹猴模型中,比较了在感染后第3天开始单独或联合使用天花疫苗ACAM2000和抗病毒药物tecovirimat的治疗效果。单独暴露后给予ACAM2000不能提供针对严重猴痘疾病或死亡的任何保护。相比之下,单独或与ACAM2000联合使用tecovirimat进行暴露后治疗可提供完全保护。此外,将tecovirimat治疗延迟至感染后第4、5或6天,有效率分别为83%(第4天和第5天)或50%(第6天)。